Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycopyranosyl lipid adjuvant - Immune Design

Next Previous
Drug Profile

Glycopyranosyl lipid adjuvant - Immune Design

Alternative Names: G 100; GLA; GLA-SE; Glucopyranosyl lipid adjuvant; Glycopyranosyl lipid A; ID-G100

Latest Information Update: 30 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immune Design
  • Developer Immune Design; Merck & Co
  • Class Adjuvants; Anti-infectives; Antiallergics; Antineoplastics; Antivirals; Hepatoprotectants; Small molecules; Urologics
  • Mechanism of Action Toll-like receptor 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Follicular lymphoma
  • No development reported Merkel cell carcinoma; Soft tissue sarcoma

Most Recent Events

  • 30 Nov 2022 No development reported - Phase-II for Follicular lymphoma (Combination therapy) in USA, France, Spain, United Kingdom (Intratumoural)
  • 30 Jun 2020 Immune Design terminates a phase-I/II clinical trials in Follicular lymphoma in United Kingdom, Spain and France and USA due to business reasons(Intratumoural) (NCT02501473) (EudraCT2015-005382-23)
  • 28 Nov 2019 No recent reports of development identified for phase-I development in Soft tissue sarcoma(Combination therapy, Late-stage disease, Metastatic disease) in USA (Intratumoural)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top